OncoMatch/Clinical Trials/NCT05317858
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Is NCT05317858 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for brain tumor.
Treatment: Blood Brain Barrier Opening - Oncology · Pembrolizumab · Atezolizumab · Cemiplimab · Nivolumab · Iptilimumab — The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Joseph's Hospital and Medical Center · Phoenix, Arizona
- Miami Cancer Institute at Baptist Health · Miami, Florida
- Moffitt Cancer Center · Tampa, Florida
- University of Maryland · Baltimore, Maryland
- Atrium Health Wake Forest Baptist · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify